Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments

Pre-exposure prophylaxis (PrEP) against HIV infection with tenofovir/emtricitabine is proven to be effective yet uptake of this preventive measure has been difficult due to several barriers such as cost, access, and misinformation. Certain subpopulations are disproportionately affected by this probl...

Full description

Saved in:
Bibliographic Details
Published in:HIV/AIDS (Auckland) 2020-01, Vol.12, p.283-293
Main Authors: Ozdener-Poyraz, Ayse Elif, Slugocki, Malgorzata, Kalabalik-Hoganson, Julie, Han, Jayoung
Format: Article
Language:English
Subjects:
Antiretroviral agents
Antiretroviral drugs
Biological products industry
Clinical trials
Contraindications
Disease prevention
Drug approval
Drug stores
Drug therapy
Emtricitabine
FDA approval
Highly active antiretroviral therapy
HIV
HIV infections
hiv prevention
Human immunodeficiency virus
Infections
Infectious diseases
medications
Patient compliance
Patients
Physicians
pre-exposure prophylaxis
prep uptake
Primary care
Prophylaxis
Review
Sexually transmitted disease prevention
Sexually transmitted diseases
Subpopulations
Tenofovir
Vagina
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pre-exposure prophylaxis (PrEP) against HIV infection with tenofovir/emtricitabine is proven to be effective yet uptake of this preventive measure has been difficult due to several barriers such as cost, access, and misinformation. Certain subpopulations are disproportionately affected by this problem. Several methods have been developed to close the gap in care. New antiretroviral treatment strategies are being investigated for safety and efficacy in preventing HIV infection. Keywords: pre-exposure prophylaxis, HIV prevention, PrEP uptake, medications
ISSN:1179-1373
1179-1373
DOI:10.2147/HIV.S216024